KRAS and cancer: Our MD simulations of wild-type and mutated K-Ras4B in the different states unraveled the mechanisms of how oncogenic mutations affect the GAP-mediated GTP hydrolysis as well as the mutational biases in K-Ras4B-driven cancers.